Pfizer Inc. (FRA:PFEB)
Germany · Delayed Price · Currency is EUR | Market Cap | 130.08B +10.7% |
| Revenue (ttm) | 53.30B -1.6% |
| Net Income | 6.62B -3.2% |
| EPS | 1.16 -3.4% |
| Shares Out | n/a |
| PE Ratio | 19.65 |
| Forward PE | 8.99 |
| Dividend | 0.48 (6.60%) |
| Ex-Dividend Date | Jan 23, 2026 |
| Volume | n/a |
| Average Volume | 40 |
| Open | 7.30 |
| Previous Close | 7.35 |
| Day's Range | 7.30 - 7.30 |
| 52-Week Range | 5.80 - 8.25 |
| Beta | n/a |
| RSI | 46.81 |
| Earnings Date | May 5, 2026 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It als... [Read more]
Financial Performance
In 2025, Pfizer's revenue was $62.58 billion, a decrease of -1.65% compared to the previous year's $63.63 billion. Earnings were $7.77 billion, a decrease of -3.24%.
Financial numbers in USD Financial StatementsNews
Pfizer Declares Second-Quarter 2026 Dividend
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2026 dividend on the company's common stock, payable June 12, 2026, to ho...
Pfizer GLP-1 weight loss drug available for pre-order in China
Pfizer's GLP-1 weight management treatment Xianweiying is available for pre-order in China, a Reuters check on a local e-commerce platform showed, ramping up competition with rivals in a market anal...
Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present new data across its diverse, industry-leading Oncology pipeline and portfolio at the American Society of Clinical Oncology (ASCO) Annual...
Pfizer's Strategy and Innovation Officer Andrew Baum to leave drugmaker, analyst note says
Pfizer's Chief Strategy and Innovation Officer, Andrew Baum, is transitioning to a new role and will eventually leave the company as part of the U.S. drugmaker's strategic simplification, according ...
U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Submission based on statistically significant event-free and overall survival data from the Phase 3 EV-304 trial Building on the existing indication in cisplatin-ineligible muscle-invasive bladder can...
The Big 3: PFE, V, SYF
Dan Deming is impressed with the sharp stock market rally to all-time highs, though he urges caution for a potential stall in the price action. For today's Big 3, he sees Pfizer's (PFE) support making...
Big Pharma Is Turning to China for the Newest Drug Ideas
China's biotechs are faster and have lower costs, and its drug research threatens to soon overtake the West's
Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual 2026 Annual Meeting of Shareholders on Thursday, April...
Why Is Pfizer Stock Dropping Tuesday?
Pfizer sentiment is also getting tugged by Washington policy risk after a potential 100% tariffs framework surfaced for drugmakers without pricing deals, with an announcement timeline as soon as Thurs...
Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs
The Trump administration is preparing to impose new tariffs on branded drugs from pharmaceutical companies that have not struck landmark deals with the president to lower their U.S. drug prices, CNBC ...
Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles
Vaccine makers Pfizer and BioNTech have halted recruitment for a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too low ...
Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines
A Belgian court on Wednesday ordered Poland and Romania to take delivery of 1.9 billion euros ($2.2 billion) worth of COVID-19 vaccines made by U.S. drugmaker Pfizer.
Pharma Offers Defensive Plays in an Uncertain Market. Charts Say Buy These 2 Stocks.
Technical indicators for Pfizer and GSK have turned bullish.
Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, ...
An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive
The drugmaker is seeking regulatory review for the first new shot to combat the disease in decades.
Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive
The Phase 3 VALOR trial results showed that fewer Lyme disease cases were accrued than anticipated, and the primary endpoint was not met in the first analysis.
Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss
Pfizer said it will seek regulatory approval for a Lyme disease vaccine candidate despite failing a late-stage trial. Pfizer said not enough people contracted Lyme disease to be confident in the resul...
Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial
Pharmaceutical giant Pfizer and French partner Valneva on Monday said they planned to seek regulatory approval for a Lyme disease vaccine after a late-stage trial.
Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial
Pharmaceutical giant Pfizer and French vaccine maker Valneva reported positive topline results from their phase three study of a vaccine candidate for Lyme disease.
Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial
U.S. drugmaker Pfizer and France's Valneva said on Monday their experimental Lyme disease vaccine showed more than 70% efficacy in a late-stage trial.
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial
NEW YORK & LYON, France--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced topline results from the Phase 3 VALOR “Vaccine Against Lyme for Ou...
5 ‘Healthy' Dividends Paying Up To 14.1%
Healthcare dividend stocks are selling off with the turbulence in the Middle East.
Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that it has received notice of an unsolicited mini-tender offer by Tutanota LLC (“Tutanota”) to purchase up to 1 million shares of Pf...
TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhib...
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...